Visible Genomics, founded with a mission to empower individuals with knowledge about their eye health, specializes in providing clinically validated, state-of-the-art risk assessments for age-related macular degeneration (AMD). The company offers genetic testing services that help predict the risk of developing AMD, enabling early intervention and personalized care. Their market focus includes individuals at risk of AMD, healthcare providers, and researchers in ophthalmology.
Notable affiliated people include a dedicated clinical advisory board comprising experts in genetics and ophthalmology. Visible Genomics has garnered attention for its innovative approach to AMD risk assessment, contributing significantly to preventive eye care. By offering accessible and reliable genetic testing, the company has made a substantial impact on improving patient outcomes and advancing the understanding of AMD.
